AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 251 min read$ORIC

Piscitelli Dominic sold $8K of ORIC

Piscitelli Dominic (Chief Financial Officer) sold 600 shares of Oric Pharmaceuticals, Inc. (ORIC) at an average of $13.50 ($13.50–$13.50) across 2 trades on 2026-09-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Piscitelli Dominic
Published Sep 25, 2026, 11:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 26, 2026, 12:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ORIC
Neutral
high confidence
Mentioned
$ORIC
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORICNeutralLow
01

Why it matters

The transaction is modest and unlikely to affect the stock materially.

02

Market read

Limited relevance; typical insider sale with minimal market impact.

03

What to watch

Potential upcoming corporate actions not disclosed

Relevance 2/10Novelty 4/10Timing: post‑market 2026‑09‑24

Background

Form 4 filing by Oric Pharmaceuticals CFO discloses a small open‑market sale under a pre‑arranged plan.

Company-level read

Ticker impact

$ORICNeutralHigh confidence
Context

CFO sold 600 shares for $8.1K via a 10b5‑1 plan on 2026‑09‑24

Expected impact

No material move expected

Evidence & confidence

Small insider sale by a senior officer, pre‑arranged plan, low dollar amount

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale could be interpreted as lack of confidence, but 10b5‑1 plans are routine

Key entities

  • Company
    Oric Pharmaceuticals, Inc.

    US‑listed biotech (ticker ORIC)

  • Executive
    Dominic Piscitelli

    Chief Financial Officer of Oric

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ORIC insider trading history →

Related articles

OCT 5
$ORICLow

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

ORIC Pharmaceuticals (ORIC) partnered with Cancer Research UK to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development. Cancer Research UK will fund and execute early clinical trials, while ORIC retains an option to reacquire rights post-Phase 1/2 data. ORIC-259 targets CIP2A, a protein linked to cancer progression, with promising preclinical data showing antitumor activity in HRD cancers.

globenewswire.com2 min
SEP 15
$ORICMedAI 8/10

ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch

ORIC Pharmaceuticals (ORIC) reported Q2 results, launching a Phase 3 trial for its prostate cancer drug rinzimetostat. The company has $387.6M in cash, funding operations into 2028. R&D costs rose to $36.3M, widening net loss to $41.5M. ORIC also advanced its lung cancer program enozertinib, with data expected later this year.

yahoo.com2 min
AUG 3
$ORICMed

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Ba

SEC EDGAR 8-K6 min